Australia
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...
2026-02-16 22:03
5341
Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...
2026-02-06 20:00
5441
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...
2026-01-30 21:00
8781
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....
2026-01-27 21:00
7887
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, theMyriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in theJournal of Trauma and Injury. MASTRR is t...
2026-01-23 03:13
4425
Hydrexia to Provide Hydrogen Application Solution to Toyota
SIDNEY, Jan. 22, 2026 /PRNewswire/ -- Hydrexia Pty Ltd, the wholly owned subsidiary of Hydrexia Holding Limited (Hydrexia), a leading hydrogen technology solution provider, announced today that it has secured an order to provide The Toyota Motor Corporation Australia Ltd (TMCA) with a number o...
2026-01-22 23:00
5695
GAC Enters Australia with AION V, M8 PHEV and EMZOOM; Launches Australian Local Strategy to Build a Benchmark Market in the South Pacific
SYDNEY, Jan. 21, 2026 /PRNewswire/ -- On November 18, 2025, GAC hosted its brand and new model launch ceremony inSydney, officially unveiling its Australia Local Strategy—"GAC: Growing Australian Confidence"—the localized implementation of the company's global "One GAC 2.0" strategy. One of the ...
2026-01-22 09:51
4137
Life's Moments App Launches Worldwide on iPhone and Android -- Turning Scattered Photos, Family Memories and Pet Moments into One Organized Family Tree
All Your Family's Memories… Finally Organized ADELAIDE, Australia, Jan. 20, 2026 /PRNewswire/ -- Life's Moments App today announced its global launch on iPhone and Android, giving families and pet owners an intuitive way to capture, store and organize photos, videos, milestones and important rec...
2026-01-20 21:07
5382
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...
2026-01-15 22:02
5000
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...
2026-01-08 22:00
1544
Seeing Machines to unveil 3D Cabin Perception Mapping at CES2026
Pioneering interior sensing technology to advance automotive safety and customer experience CANBERRA, Australia, Jan. 5, 2026 /PRNewswire/ -- Seeing Machines, a global leader in vision-based monitoring technology, today announced it will unveil its next-generation 3D Cabin Perception Mapping sol...
2026-01-05 20:00
1530
Seeing Machines Announces Future Mobility Group, established to deepen integration with Autonomous Vehicle programs
CANBERRA, Australia, Jan. 2, 2026 /PRNewswire/ -- Seeing Machines, a global leader in vision-based monitoring technology, has established a dedicated Future Mobility Group to support increasing demand from the autonomous driving sector and to advance new commercial opportunities as automated vehi...
2026-01-02 21:00
269
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an ...
2025-12-24 22:02
3134
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therap...
2025-12-22 21:00
5730
BUMA Australia Secures AU$740 Million Multi-Year Contract Extension with Whitehaven at Blackwater Mine Through 2030
* BUMA Australia Pty Ltd ("BUMA Australia"), a wholly owned subsidiary of PT Bukit Makmur Mandiri Utama ("BUMA"), under PT BUMA Internasional Grup Tbk ("BUMA International Group"; IDX: DOID), has secured a multi-year contract extension valued at approximately AU$740 million with Blackwater Oper...
2025-12-22 13:35
2859
Global study targets dengue as disease threatens nearly half the world's population
LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models have been published, but few have been tested in real public-health settings. Now, researchers from the US andAustralia are launching a field evaluation inVietnam to see whether a new early-warning platform c...
2025-12-18 21:01
3583
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
Highlights: * FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol * This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial * Next steps include obtaining single IRB approval, site initiations and cl...
2025-12-12 04:49
2116
Solace and NetComm Commercialize World's First Wirelessly Powered, Window-Mounted 5G CPE
MOUNT PEARL, NL and SYDNEY, Dec. 11, 2025 /PRNewswire/ -- Solace Power Inc. ("Solace") and NetComm Wireless ("NetComm") today announced a strategic partnership to co-develop and commercialize the world's first wirelessly powered, window-mounted outdoor 5G customer premises equipment (CPE). The p...
2025-12-11 13:00
1639
Razor Labs Launches DataMind AI™ 4.5, a Major Leap Forward in Predictive Maintenance and Fleet Management for Mining Operations
SYDNEY, Dec. 11, 2025 /PRNewswire/ -- Razor Labs
2025-12-11 05:00
1620
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions...
2025-12-10 21:00
5514
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 322 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 292 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09